Partners & Integrations
Working side by side with clinicians and hospitals at every step
Innovation does not happen in a bubble. Progress cannot be achieved alone. As we work to improve patient outcomes and transform the fight against cancer, Accuray continually collaborates with established leaders and emerging pioneers in radiation oncology and in medical physics. We share knowledge, build partnerships and integrate the best technologies with our products. Collaborating with clinical groups, device manufacturers, technology companies and other organizations, we bring our respective strengths and capabilities together to create powerful synergies that serve our common goal: enabling patients to live longer, better lives. We invite you to explore these partnerships and integrations below.
The partnership between Accuray and Brainlab enables the neuro-radiosurgery community to leverage the powerful precision of Accuray treatment delivery technologies in combination with Brainlab Elements planning software, which delivers contouring capabilities optimized for neurosurgeons. This partnership will also enhance the interoperability of Accuray treatment planning software with Snke OS, the Brainlab health tech platform, to improve the experience for both those administering and receiving radiation treatments. This interoperability will also allow customers to add CyberKnife® treatment data via Quentry, the Brainlab patient registry platform, and enable their participation in neuro-radiosurgery patient registries to help improve patient outcomes. To learn more about Brainlab, visit brainlab.com
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Devices Co Ltd. In China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit http://www.c-rad.com.
Limbus AI has partnered with Accuray in the development of Accuray’s next generation adaptive treatment application.
Limbus AI specializes in the creation of artificial intelligence (AI)-driven automatic contouring algorithms with a focus on contour accuracy – a necessity for efficient treatment planning and adaptive therapy. Our passionate team of healthcare and technology specialists is dedicated to improving cancer care through the development of state-of-the-art software and we are proud to be working collaboratively with Accuray. Limbus AI is headquartered in Regina Saskatchewan, Canada.
The partnership between Accuray and RaySearch is built upon a long-term collaboration agreement to develop and market fully integrated solutions that combine the RayStation advanced treatment planning system with the CyberKnife® and Radixact®, the next generation TomoTherapy®platform, and RayCare oncology information system (OIS). This seamless integration gives greater flexibility to hospitals and clinics with multiple treatment systems, enabling clinical teams to leverage RaySearch software with powerful Accuray treatment technologies. To learn more about RaySearch, visit raysearchlabs.com.
In collaboration with Accuray, ScandiDos has developed a solution that enhances the quality assurance (QA) of Radixact® Synchrony® real-time delivery adaptation. The solution independently simulates the breathing motion of patients, therefore, adding an extra dimension of QA to the already existing product, the ScandiDos Delta4 HexaMotion motion platform. Delta4 HexaMotion is a motion platform that recreates the movement of the tumor in six dimensions, whereas the Delta4 Phantom+ measures the 4D dose distribution and shows exactly where the dose ends up. The new Independent Motion Platform (IMP) option for the Delta4 HexaMotion is developed in close collaboration with Accuray, and its purpose is to mimic the breathing of the patient independent of the motion of the tumor. The Delta4 software allows you to run the Delta4 HexaMotion movement and the IMP movement with a phase shift in order to properly simulate the actual patient situation. Thus, providing medical physicists with a realistic pre-treatment verification of the delivered treatment for Accuray Radixact with Synchrony. To learn more about Delta4 by ScandiDos, visit.